{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T07:33:48Z","timestamp":1777880028360,"version":"3.51.4"},"reference-count":46,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Infection"],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Severe gram-positive infections are frequent in people who inject drugs, and successful completion of treatment presents unique challenges in this population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>We aimed to evaluate the feasibility of a long-acting antibiotic, dalbavancin, as an alternative to standard-of-care antibiotics for severe infections due to vancomycin-susceptible pathogens requiring \u2a7e2\u2009weeks of therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>We designed an investigator-initiated single-arm unblinded prospective cohort study to evaluate the safety and efficacy of an early switch to dalbavancin in two doses administered 1\u2009week apart.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We screened patients admitted with bloodstream infection, osteomyelitis, septic arthritis, infective endocarditis or deep abscesses, and comorbid substance use disorder (SUD) for eligibility. Consenting patients were switched to dalbavancin within 7\u2009days from their index culture. They were monitored in the hospital for efficacy and safety of the treatment until the second dose of dalbavancin 7\u2009days later and then discharged if stable. Study participants were evaluated with a decision support engine for a hypothetical appropriate level of care regarding their SUD after discharge. Their follow-up was planned for 12\u2009months from the index culture, either in-person or via telehealth\/telephone.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>The enrollment was terminated early due to significant loss-to-follow-up. In all, 11 patients were enrolled, 4 completed 12\u2009months of follow-up, 2 completed 8\u2009months of follow-up, and 1 was seen once after discharge. The remaining five patients were lost to follow-up immediately after discharge. All 11 patients continued to improve after switching to dalbavancin between the first and second doses. There were two per-protocol failures of treatment. Dalbavancin was well tolerated, though some adverse events were reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Dalbavancin may be a safe and effective alternative for an early switch in treating severe gram-positive infections.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration:<\/jats:title>\n                    <jats:p>The trial was registered as NCT04847921 with clinicaltrials.gov.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/20499361231223889","type":"journal-article","created":{"date-parts":[[2024,1,17]],"date-time":"2024-01-17T09:13:16Z","timestamp":1705482796000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Substance use disorder-associated infections\u2019 treatment with dalbavancin enabling outpatient transition (SUDDEN OUT) \u2013 an investigator-initiated single-arm unblinded prospective cohort study"],"prefix":"10.1177","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1746-7462","authenticated-orcid":false,"given":"Martin","family":"Krsak","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, University of Colorado School of Medicine, Mail Stop B163, Anschutz Outpatient Pavilion, 1635 Aurora Court, Aurora, CO 80045-2581, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sias","family":"Scherger","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, University of Colorado School of Medicine, Aurora, CO, USA"},{"name":"Division of Infectious Diseases, University of Nebraska School of Medicine, Omaha, NE, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew A.","family":"Miller","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Children\u2019s Hospital Colorado, Aurora, CO, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Cobb","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, University of Colorado School of Medicine, Aurora, CO, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian T.","family":"Montague","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, University of Colorado School of Medicine, Aurora, CO, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7363-8652","authenticated-orcid":false,"given":"Andr\u00e9s F.","family":"Henao-Mart\u00ednez","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, University of Colorado School of Medicine, Aurora, CO, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyle C.","family":"Molina","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, University of Colorado School of Medicine, Aurora, CO, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2024,1,17]]},"reference":[{"key":"bibr1-20499361231223889","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.9743"},{"key":"bibr2-20499361231223889","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir034"},{"key":"bibr3-20499361231223889","volume":"68","author":"Norris AH","year":"2018","journal-title":"Clin Infect Dis"},{"key":"bibr4-20499361231223889","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2015.07.001"},{"key":"bibr5-20499361231223889","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv344"},{"key":"bibr6-20499361231223889","doi-asserted-by":"publisher","DOI":"10.1002\/jhm.2582"},{"key":"bibr7-20499361231223889","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.130029"},{"key":"bibr8-20499361231223889","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2015.302885a"},{"key":"bibr9-20499361231223889","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0024459"},{"key":"bibr10-20499361231223889","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200401010-00008"},{"key":"bibr11-20499361231223889","unstructured":"Manufacturer\u2019s highlights of prescribing information, https:\/\/www.allergan.com\/assets\/pdf\/dalvance_pi (accessed 2 October 2023)."},{"key":"bibr12-20499361231223889","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofy331"},{"key":"bibr13-20499361231223889","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04550-14"},{"key":"bibr14-20499361231223889","doi-asserted-by":"publisher","DOI":"10.1086\/427283"},{"key":"bibr15-20499361231223889","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2014.05.014"},{"key":"bibr16-20499361231223889","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy279"},{"key":"bibr17-20499361231223889","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2015.1078339"},{"key":"bibr18-20499361231223889","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2017.11.008"},{"key":"bibr19-20499361231223889","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz162"},{"key":"bibr20-20499361231223889","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofz274"},{"key":"bibr21-20499361231223889","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofac335"},{"key":"bibr22-20499361231223889","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2389"},{"key":"bibr23-20499361231223889","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6963-5-43"},{"key":"bibr24-20499361231223889","doi-asserted-by":"publisher","DOI":"10.1086\/420818"},{"key":"bibr25-20499361231223889","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa053783"},{"key":"bibr26-20499361231223889","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkp051"},{"key":"bibr27-20499361231223889","doi-asserted-by":"publisher","DOI":"10.1186\/s12941-015-0081-5"},{"key":"bibr28-20499361231223889","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2015.01.017"},{"key":"bibr29-20499361231223889","volume-title":"ASAM criteria","author":"American Society of Addiction Medicine, Inc","year":"2013","edition":"3"},{"key":"bibr30-20499361231223889","unstructured":"ASAM Continuum\u2122, https:\/\/www.asamcontinuum.org\/ (accessed 26 November 2018)."},{"key":"bibr31-20499361231223889","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2008.08.010"},{"key":"bibr32-20499361231223889","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1497.2006.00398.x"},{"key":"bibr33-20499361231223889","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000000165"},{"key":"bibr34-20499361231223889","first-page":"89","volume":"26","author":"Bruce RD.","year":"2018","journal-title":"Top Antivir Med"},{"key":"bibr35-20499361231223889","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2018.5220"},{"key":"bibr36-20499361231223889","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy924"},{"key":"bibr37-20499361231223889","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2017.05.007"},{"key":"bibr38-20499361231223889","volume":"102","author":"Weinstein ZM","year":"2018","journal-title":"Med Clin North Am"},{"key":"bibr39-20499361231223889","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1606157"},{"key":"bibr40-20499361231223889","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2020.01.010"},{"key":"bibr41-20499361231223889","doi-asserted-by":"publisher","DOI":"10.1111\/add.14892"},{"key":"bibr42-20499361231223889","doi-asserted-by":"publisher","DOI":"10.1002\/jhm.2597"},{"key":"bibr43-20499361231223889","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199806113382406"},{"key":"bibr44-20499361231223889","doi-asserted-by":"publisher","DOI":"10.1001\/jama.285.2.200"},{"key":"bibr45-20499361231223889","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ750"},{"key":"bibr46-20499361231223889","unstructured":"Drozd EM, Hoban N. Impact on Medicare expenditures from expanding coverage of infusion therapy of anti-infective drugs to the home setting, http:\/\/www.nhia.org\/resource\/legislative\/documents\/AvalereFinalHomeInfusionReport.pdf (2014, accessed 3 September 2019)."}],"container-title":["Therapeutic Advances in Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20499361231223889","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/20499361231223889","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20499361231223889","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T23:59:58Z","timestamp":1777593598000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/20499361231223889"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":46,"alternative-id":["10.1177\/20499361231223889"],"URL":"https:\/\/doi.org\/10.1177\/20499361231223889","relation":{},"ISSN":["2049-9361","2049-937X"],"issn-type":[{"value":"2049-9361","type":"print"},{"value":"2049-937X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1]]},"article-number":"20499361231223889"}}